Vantage Oncology, LLC Sustainability Profile
Vantage Oncology, LLC, a prominent player in the oncology sector, is headquartered in the United States and operates extensively across various regions. Founded in 2006, the company has established itself as a leader in providing advanced radiation therapy solutions, focusing on enhancing patient care through innovative technologies. Specialising in comprehensive cancer treatment services, Vantage Oncology offers a range of core products, including state-of-the-art radiation therapy systems and treatment planning software. Their commitment to precision and patient-centric care sets them apart in the competitive landscape of oncology services. With a strong market position, Vantage Oncology has achieved notable milestones, including partnerships with leading healthcare institutions and recognition for their contributions to cancer treatment advancements. Their dedication to improving patient outcomes continues to drive their success in the ever-evolving field of oncology.
DitchCarbon Score
How does Vantage Oncology, LLC's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Vantage Oncology, LLC's score of 47 is higher than 72% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Vantage Oncology, LLC, headquartered in the US, currently does not have specific carbon emissions data available for the most recent year, as indicated by the absence of reported figures. The company is a current subsidiary of McKesson Corporation, which may influence its climate commitments and emissions reporting. As part of its corporate family, Vantage Oncology's climate initiatives and reduction targets are likely aligned with those of McKesson Corporation. However, no specific reduction targets or achievements have been disclosed for Vantage Oncology itself. The absence of data suggests that the company may still be in the process of establishing its own emissions metrics or climate strategies. Given the lack of direct emissions data, it is essential to consider the broader context of McKesson Corporation's sustainability efforts, which may include initiatives aimed at reducing carbon footprints across its subsidiaries. Vantage Oncology's commitment to climate action may be informed by McKesson's overarching sustainability goals, although specific details on these initiatives are not provided. In summary, while Vantage Oncology, LLC does not currently report its carbon emissions or specific climate commitments, it is positioned within a corporate structure that may influence its environmental strategies through its relationship with McKesson Corporation.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2016 | 2017 | 2018 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|
| Scope 1 | 92,194,000 | 00,000,000 | 000,000,000 | 00,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 188,912,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | 28,733,000 | 00,000,000 | 00,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 |
How Carbon Intensive is Vantage Oncology, LLC's Industry?
How Carbon Intensive is Vantage Oncology, LLC's Location?
Vantage Oncology, LLC's Scope 3 Categories Breakdown
Vantage Oncology, LLC's Scope 3 emissions, which increased by 12% last year and increased significantly since 2016, demonstrating supply chain emissions tracking. Nearly all of their carbon footprint comes from suppliers and value chain emissions, representing nearly all emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 98% of Scope 3 emissions.
Top Scope 3 Categories
Vantage Oncology, LLC's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Vantage Oncology, LLC has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
